ZA201704977B - Use of short chain fatty acids in cancer prevention - Google Patents
Use of short chain fatty acids in cancer preventionInfo
- Publication number
- ZA201704977B ZA201704977B ZA2017/04977A ZA201704977A ZA201704977B ZA 201704977 B ZA201704977 B ZA 201704977B ZA 2017/04977 A ZA2017/04977 A ZA 2017/04977A ZA 201704977 A ZA201704977 A ZA 201704977A ZA 201704977 B ZA201704977 B ZA 201704977B
- Authority
- ZA
- South Africa
- Prior art keywords
- fatty acids
- chain fatty
- short chain
- cancer prevention
- cancer
- Prior art date
Links
- 206010028980 Neoplasm Diseases 0.000 title 1
- 201000011510 cancer Diseases 0.000 title 1
- 230000002265 prevention Effects 0.000 title 1
- 235000021391 short chain fatty acids Nutrition 0.000 title 1
- 150000004666 short chain fatty acids Chemical class 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/194—Carboxylic acids, e.g. valproic acid having two or more carboxyl groups, e.g. succinic, maleic or phthalic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
- A61K35/742—Spore-forming bacteria, e.g. Bacillus coagulans, Bacillus subtilis, clostridium or Lactobacillus sporogenes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
- A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
- A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
- A61K35/745—Bifidobacteria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
- A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
- A61K35/747—Lactobacilli, e.g. L. acidophilus or L. brevis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
- A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Molecular Biology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Physiology (AREA)
- Nutrition Science (AREA)
- Zoology (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Non-Alcoholic Beverages (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562106778P | 2015-01-23 | 2015-01-23 | |
| PCT/US2016/014292 WO2016118730A1 (en) | 2015-01-23 | 2016-01-21 | Use of short chain fatty acids in cancer prevention |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ZA201704977B true ZA201704977B (en) | 2022-12-21 |
Family
ID=56417737
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ZA2017/04977A ZA201704977B (en) | 2015-01-23 | 2017-07-21 | Use of short chain fatty acids in cancer prevention |
Country Status (12)
| Country | Link |
|---|---|
| US (6) | US10231941B2 (https=) |
| EP (1) | EP3247342B1 (https=) |
| JP (4) | JP6783247B2 (https=) |
| KR (1) | KR102735818B1 (https=) |
| CN (2) | CN107405321A (https=) |
| AU (3) | AU2016209244A1 (https=) |
| IL (1) | IL253581A0 (https=) |
| MX (1) | MX387817B (https=) |
| RU (1) | RU2017127597A (https=) |
| SG (2) | SG11201705953XA (https=) |
| WO (1) | WO2016118730A1 (https=) |
| ZA (1) | ZA201704977B (https=) |
Families Citing this family (49)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB201112091D0 (en) | 2011-07-14 | 2011-08-31 | Gt Biolog Ltd | Bacterial strains isolated from pigs |
| GB201117313D0 (en) | 2011-10-07 | 2011-11-16 | Gt Biolog Ltd | Bacterium for use in medicine |
| GB201306536D0 (en) | 2013-04-10 | 2013-05-22 | Gt Biolog Ltd | Polypeptide and immune modulation |
| SG10201903823QA (en) | 2014-10-31 | 2019-05-30 | Whole Biome Inc | Methods and compositions relating to microbial treatment and diagnosis of disorders |
| WO2016102950A1 (en) | 2014-12-23 | 2016-06-30 | 4D Pharma Research Limited | Immune modulation |
| SG11201704814SA (en) | 2014-12-23 | 2017-07-28 | 4D Pharma Res Ltd | Pirin polypeptide and immune modulation |
| HRP20191949T1 (hr) | 2015-06-15 | 2020-01-24 | 4D Pharma Research Limited | Blautia stercosis i wexlerae za upotrebu u liječenju upalnih i autoimunih bolesti |
| ME03511B (me) | 2015-06-15 | 2020-04-20 | 4D Pharma Res Ltd | Kompozicije koje sadrže bakterijske sojeve |
| WO2016203221A1 (en) | 2015-06-15 | 2016-12-22 | 4D Pharma Research Limited | Compositions comprising bacterial strains |
| MA41010B1 (fr) | 2015-06-15 | 2020-01-31 | 4D Pharma Res Ltd | Compositions comprenant des souches bactériennes |
| MA41060B1 (fr) | 2015-06-15 | 2019-11-29 | 4D Pharma Res Ltd | Compositions comprenant des souches bactériennes |
| HK1254843B (zh) | 2015-11-20 | 2020-04-17 | 希杰生物科技株式会社 | 包含细菌菌株的组合物 |
| GB201520497D0 (en) | 2015-11-20 | 2016-01-06 | 4D Pharma Res Ltd | Compositions comprising bacterial strains |
| GB201520631D0 (en) | 2015-11-23 | 2016-01-06 | 4D Pharma Res Ltd | Compositions comprising bacterial strains |
| GB201520638D0 (en) | 2015-11-23 | 2016-01-06 | 4D Pharma Res Ltd | Compositions comprising bacterial strains |
| GB201612191D0 (en) | 2016-07-13 | 2016-08-24 | 4D Pharma Plc | Compositions comprising bacterial strains |
| SG10201913557TA (en) | 2016-03-04 | 2020-02-27 | 4D Pharma Plc | Compositions comprising bacterial blautia strains for treating visceral hypersensitivity |
| TWI802545B (zh) | 2016-07-13 | 2023-05-21 | 英商４Ｄ製藥有限公司 | 包含細菌菌株之組合物 |
| WO2018089861A1 (en) * | 2016-11-11 | 2018-05-17 | The Regents Of The University Of California | Methods and compositions for the treatment of cancer and metabolic diseases |
| GB201621123D0 (en) | 2016-12-12 | 2017-01-25 | 4D Pharma Plc | Compositions comprising bacterial strains |
| US11065217B2 (en) | 2017-01-27 | 2021-07-20 | Temple University—Of the Commonwealth System of Higher Education | Use of short chain fatty acids for the treatment and prevention of diseases and disorders |
| EP3612570A4 (en) | 2017-04-17 | 2021-01-13 | The University of Chicago | POLYMERIC MATERIALS FOR THE ADMINISTRATION OF SHORT-CHAIN FATTY ACIDS TO THE INTESTINE FOR HUMAN HEALTH AND DISEASE TREATMENT APPLICATIONS |
| US20220304967A1 (en) * | 2017-04-24 | 2022-09-29 | Allerpops | Oral microbiota promoting composition cross-reference to related applications |
| ES2877726T3 (es) | 2017-05-22 | 2021-11-17 | 4D Pharma Res Ltd | Composiciones que comprenden cepas bacterianas |
| EP3630942B1 (en) | 2017-05-24 | 2022-11-30 | 4D Pharma Research Limited | Compositions comprising bacterial strain |
| ES2841902T3 (es) | 2017-06-14 | 2021-07-12 | 4D Pharma Res Ltd | Composiciones que comprenden cepas bacterianas |
| PL3600363T3 (pl) | 2017-06-14 | 2021-06-14 | 4D Pharma Research Limited | Kompozycje zawierające szczepy bakteryjne |
| TWI812624B (zh) | 2017-06-14 | 2023-08-21 | 南韓商希杰生物科技股份有限公司 | 包含細菌品系之組成物 |
| MA51770A (fr) | 2017-07-05 | 2020-05-13 | Evelo Biosciences Inc | Compositions et méthodes de traitement du cancer à l'aide de bifidobacterium animalis ssp. lactis |
| CN111372477B (zh) * | 2017-08-04 | 2024-05-24 | 雀巢产品有限公司 | 在含有gos的培养基中预调理的益生菌及其用途 |
| CN111372596A (zh) | 2017-08-30 | 2020-07-03 | 潘德勒姆治疗公司 | 用于治疗微生物组相关病症的方法和组合物 |
| CN110090230B (zh) * | 2018-01-30 | 2022-07-12 | 青岛东海药业有限公司 | 凝结芽孢杆菌在制备预防或治疗胆管癌制剂中的应用 |
| SG11202011031UA (en) * | 2018-05-11 | 2020-12-30 | 4D Pharma Res Ltd | Compositions comprising bacterial strains |
| SG11202011817WA (en) * | 2018-06-01 | 2020-12-30 | Evolve Biosystems Inc | Compositions and methods to promote host defense and stimulate, expand, and/or reset t cell repertoires |
| CA3106315A1 (en) | 2018-07-19 | 2020-01-23 | Pendulum Therapeutics, Inc. | Methods and compositions for microbial engraftment |
| EP4034096B1 (en) * | 2019-09-25 | 2025-12-31 | Philipps-Universität Marburg | SHORT-CHAIN FATTY ACID PENTANOATE AS AN ACTIVATOR FOR CELL THERAPY AND ANTITUMOR THERAPY |
| KR102510198B1 (ko) * | 2019-11-14 | 2023-03-15 | 가톨릭대학교 산학협력단 | 락토바실러스 속 균주 및 SCFA(Short fatty chain acid)를 포함하는 면역 질환의 예방 및 치료용 조성물 |
| TWI734341B (zh) * | 2020-01-14 | 2021-07-21 | 景岳生物科技股份有限公司 | 一種副乾酪乳桿菌ｇｍｎｌ-３４６用於抗口腔癌之用途 |
| JP2023517869A (ja) * | 2020-03-05 | 2023-04-27 | リスキュア・バイオサイエンシーズ・カンパニー・リミテッド | ロイコノストック属株を有効成分として含む癌の予防又は治療用医薬組成物 |
| US20240009154A1 (en) * | 2020-08-04 | 2024-01-11 | Temple University-Of The Commonwealth System Of Higher Education | Methods and compositions for treating cytokine release syndrome |
| US11938152B2 (en) | 2020-08-06 | 2024-03-26 | Kedar N Prasad | High-dose antioxidants in cancer treatment |
| JP2023549522A (ja) * | 2020-11-12 | 2023-11-27 | テンプル・ユニバーシティ－オブ・ザ・コモンウェルス・システム・オブ・ハイアー・エデュケイション | がん予防における短鎖脂肪酸の使用 |
| WO2022177409A1 (ko) * | 2021-02-22 | 2022-08-25 | 주식회사 리스큐어바이오사이언시스 | 류코노스톡 메센테로이데스 균주 유래 나노소포체를 유효성분으로 포함하는 암의 예방 또는 치료용 약학 조성물 |
| WO2023141202A1 (en) * | 2022-01-19 | 2023-07-27 | Hodgdon Ian | Short-chain fatty acids for cancer treatment |
| CN117925434B (zh) * | 2022-10-26 | 2025-02-14 | 慕恩（广州）生物科技有限公司 | 粪肠球菌mnh 22871及其应用 |
| CN116212027A (zh) * | 2023-02-28 | 2023-06-06 | 西湖大学 | 一种调控Treg细胞内铁水平的试剂的用途 |
| WO2025176152A1 (en) * | 2024-02-19 | 2025-08-28 | The University Of Hong Kong | Probiotics mixtures and methods of use thereof for treating cancers |
| CN119424400B (zh) * | 2024-10-21 | 2026-03-03 | 江南大学 | 缓解衰老的肠道菌群支链氨基酸代谢产物异丁酸和异戊酸及其应用 |
| CN119258047A (zh) * | 2024-11-26 | 2025-01-07 | 哈尔滨医科大学 | 琥珀酸在制备防治肝癌药物中的新用途 |
Family Cites Families (34)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4735967A (en) | 1985-05-28 | 1988-04-05 | Neesby Torben E | Method for desensitizing the gastrointestinal tract from food allergies |
| AU645070B2 (en) | 1990-04-10 | 1994-01-06 | Nb International Technologies | Use of short chain fatty acid containing lipids to maintain gastrointestinal integrity and function in patients DO NOT SEAL - SEE LETTER DATED 22.03.94 |
| PH31403A (en) | 1991-03-01 | 1998-10-29 | Warner Lambert Co | Therapeutic compositions to protect and recuscitate mammalian cells and methods for preparing same. |
| WO1995011699A1 (en) | 1993-10-29 | 1995-05-04 | The Trustees Of Boston University | Physiologically stable compositions of butyric acid, and butyric acid salts and derivatives as anti-neoplastic agents |
| JP2000072667A (ja) | 1998-08-25 | 2000-03-07 | Kurasuraa:Kk | 大腸炎治療用経口投与剤 |
| US6201077B1 (en) | 1998-12-01 | 2001-03-13 | Phillips Petroleum Company | Process that produces polymers |
| EP1034788A1 (en) | 1999-03-11 | 2000-09-13 | Société des Produits Nestlé S.A. | Lactic acid bacteria strains capable of preventing diarrhea |
| EP1463759B8 (en) | 2002-01-07 | 2013-07-10 | Euroscreen S.A. | Ligand for g-protein coupled receptor gpr43 and uses thereof |
| WO2003075839A2 (en) | 2002-03-04 | 2003-09-18 | Aton Pharma, Inc. | Methods of inducing terminal differentiation |
| CN100566711C (zh) | 2002-04-15 | 2009-12-09 | 斯隆-凯特林癌症研究院 | 治疗癌症的化合物及其用途 |
| US8846039B2 (en) | 2002-04-26 | 2014-09-30 | Asan Laboratories Company (Cayman), Limited | Method for ameliorating pruritus |
| JP2006501267A (ja) | 2002-09-13 | 2006-01-12 | バージニア コモンウェルス ユニバーシティー | 白血病の処置のためのａ）Ｎ−｛５−［４−（４−メチル−ピペラジノ−メチル）−ベンゾイルアミド］−２−メチルフェニル｝−４−（３−ピリジル）−２−ピリミジン−アミンおよびｂ）ヒストンデアセチラーゼインヒビターの組合せ剤 |
| US20050023179A1 (en) | 2003-07-31 | 2005-02-03 | Albritton Charles Wade | Fragile-product cage for vacuum packaging appliances |
| CA2535889A1 (en) | 2003-08-29 | 2005-03-17 | Aton Pharma, Inc. | Combination methods of treating cancer |
| WO2007016953A1 (en) | 2005-07-29 | 2007-02-15 | Matuschka-Greiffenclau Markus | Composition for reducing alcohol induced liver cancer risk |
| EP2007370B1 (en) | 2006-03-31 | 2013-12-18 | Erasmus University Medical Center Rotterdam | Novel composition for tumor growth control |
| WO2008054293A1 (en) * | 2006-11-03 | 2008-05-08 | Salutary Care Limited | Composition, its use for treating systemic diseases a conditions, and product containing said composition |
| US20080153908A1 (en) | 2006-12-20 | 2008-06-26 | Jani Dharmendra M | Method of Treating Mucin Deficiency with an Active Pharmaceutical and Related Composition |
| CN101959429B (zh) | 2008-01-08 | 2014-09-10 | 阿克塞利亚制药公司 | 抗微生物肽系统的激动剂 |
| CN101214234B (zh) * | 2008-01-10 | 2010-09-08 | 中国人民解放军第二军医大学 | α-羟基酸在制备癌瘤体内注射治疗药物中的应用 |
| US9339667B2 (en) | 2009-02-18 | 2016-05-17 | Sea Qiq As | Mixture of inorganic compounds, preparations containing the mixture and use of the mixture |
| EP3181134B1 (en) | 2009-06-19 | 2019-10-30 | DuPont Nutrition Biosciences ApS | Bifidobacteria for treating diabetes and related conditions |
| US8962686B2 (en) | 2010-04-28 | 2015-02-24 | The Chinese University Of Hong Kong | Method and medication for prevention and treatment of ocular hypertension and glaucoma |
| EP2389932A1 (en) | 2010-05-28 | 2011-11-30 | Lunamed AG | Compositions for use in genetic disorders comprising 4-phenyl-butyric acid and its salts |
| MX2013001190A (es) | 2010-07-29 | 2013-03-18 | Cosmo Technologies Ltd | Composiciones farmaceuticas y/o dieteticas con base en acidos grasos de cadena corta. |
| SG183544A1 (en) | 2010-11-29 | 2012-10-30 | Univ Putra Malaysia | Tumour cytotoxic agent and methods thereof |
| JP2014506923A (ja) * | 2011-03-01 | 2014-03-20 | クオラム イノベーションズ リミテッド ライアビリティ カンパニー | 病原性バイオフィルムと関連した状態を治療するための物質および方法 |
| WO2012131069A1 (en) | 2011-03-31 | 2012-10-04 | Proponent Biotech Gmbh | Short chain fatty acids and their derivatives for use in treatment immunogenic disorders |
| US9402820B2 (en) * | 2011-04-22 | 2016-08-02 | The United States Of America As Represented By The Secretary, Department Of Health And Human Services | Use of pyruvate or succinate to enhance the efficacy of a hypoxia activated prodrug for the treatment of tumors |
| SG11201402650RA (en) | 2012-01-16 | 2014-06-27 | Elizabeth Mckenna | Compositions and methods for the treatment of hepatic diseases and disorders |
| GB201215289D0 (en) | 2012-08-28 | 2012-10-10 | Medical Res Council | Nanoparticle formulation |
| TWI463986B (zh) | 2012-08-29 | 2014-12-11 | Univ China Medical | 胚芽乳酸桿菌ｃｍｕ９９５菌株之新用途 |
| WO2015006355A2 (en) | 2013-07-09 | 2015-01-15 | Puretech Ventures, Llc | Compositions containing combinations of bioactive molecules derived from microbiota for treatment of disease |
| EP3033091B1 (en) * | 2013-08-16 | 2022-09-07 | Versitech Limited | Probiotic composition and use thereof in the prevention and treatment of hepatocellular carcinoma |
-
2016
- 2016-01-21 CN CN201680017250.3A patent/CN107405321A/zh active Pending
- 2016-01-21 JP JP2017557279A patent/JP6783247B2/ja active Active
- 2016-01-21 MX MX2017009532A patent/MX387817B/es unknown
- 2016-01-21 KR KR1020177023391A patent/KR102735818B1/ko active Active
- 2016-01-21 AU AU2016209244A patent/AU2016209244A1/en not_active Abandoned
- 2016-01-21 CN CN202210967776.5A patent/CN115350171A/zh active Pending
- 2016-01-21 SG SG11201705953XA patent/SG11201705953XA/en unknown
- 2016-01-21 EP EP16740745.1A patent/EP3247342B1/en active Active
- 2016-01-21 WO PCT/US2016/014292 patent/WO2016118730A1/en not_active Ceased
- 2016-01-21 SG SG10201907660Y patent/SG10201907660YA/en unknown
- 2016-01-21 US US15/545,371 patent/US10231941B2/en active Active
- 2016-01-21 RU RU2017127597A patent/RU2017127597A/ru not_active Application Discontinuation
-
2017
- 2017-07-19 IL IL253581A patent/IL253581A0/en active IP Right Grant
- 2017-07-21 ZA ZA2017/04977A patent/ZA201704977B/en unknown
-
2018
- 2018-02-23 US US15/903,395 patent/US10143669B2/en active Active
-
2019
- 2019-01-30 US US16/261,836 patent/US20190160031A1/en not_active Abandoned
- 2019-03-15 AU AU2019201799A patent/AU2019201799B2/en active Active
-
2020
- 2020-09-23 AU AU2020239699A patent/AU2020239699A1/en not_active Abandoned
- 2020-10-21 JP JP2020176442A patent/JP2021020929A/ja active Pending
-
2021
- 2021-07-19 US US17/379,305 patent/US11963938B2/en active Active
-
2022
- 2022-12-08 JP JP2022196339A patent/JP2023027219A/ja active Pending
-
2024
- 2024-03-19 US US18/609,070 patent/US20240342122A1/en active Pending
- 2024-12-10 US US18/975,514 patent/US20250213508A1/en active Pending
- 2024-12-17 JP JP2024220908A patent/JP2025038120A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ZA201704977B (en) | Use of short chain fatty acids in cancer prevention | |
| IL256874B (en) | Immune checkpoint suppressors for use in the treatment of blood-borne cancers | |
| IL258955B2 (en) | Cancer treatment preparations and methods | |
| ZA201803742B (en) | Dihydroimidazopyrazinone derivatives useful in the treatment of cancer | |
| IL248455A0 (en) | igf-1r antibody-drug conjugate and its use for cancer treatment | |
| ZA201607540B (en) | Compositions and methods to treating hemoglobinopathies | |
| PT3200815T (pt) | Métodos e composições para o tratamento de cancro | |
| SG11201608217PA (en) | Fatty acid composition and use thereof | |
| IL280690A (en) | Pharmaceutical preparations that include DGLA and their use | |
| IL248767B (en) | Trimethoxyphenyl-benzaimidazole compounds for cancer treatment | |
| GB201420533D0 (en) | Use of Nanomaterials in treating cancer | |
| SG11201803022TA (en) | Compositions comprising fatty acids and their use | |
| IL252992A0 (en) | Grape products for non-alcoholic fatty liver disease and other uses | |
| GB201408297D0 (en) | Treatment of cancer | |
| PL3229790T3 (pl) | Kompozycje zawierające triglicerydy o średniej długości łańcucha do stosowania w leczeniu padaczki | |
| SG10202001388YA (en) | Use of ureidomustine (bo-1055) in cancer treatment | |
| PL3233074T3 (pl) | Leczenie niealkoholowych stłuszczeniowych chorób wątroby | |
| GB201417456D0 (en) | Treatment of cancer | |
| GB201410695D0 (en) | Uses of oligouronates in cancer treatment | |
| ZA201403006B (en) | Composition for use in treatment of cancer | |
| GB201419559D0 (en) | Therapeutic compositions and methods | |
| GB201409362D0 (en) | Treatment of cancer | |
| GB201405449D0 (en) | Treatment of cancer | |
| GB201405075D0 (en) | Treatment of cancer |